Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443868 | 0.95 | PDE5A (0.80) | PDE5APDE6C | |
| SCHEMBL6446061 | 0.94 | PDE5A (0.79) | PDE5APDE6C | |
| SCHEMBL6441919 | 0.94 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL314617 | 0.94 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL3680256 | 0.94 | PDE5A (0.88) | PDE5APDE6C | |
| SCHEMBL29419599 | 0.94 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6445340 | 0.93 | PDE5A (0.88) | PDE5APDE6C | |
| SCHEMBL6442028 | 0.93 | PDE5A (0.85) | PDE5APDE6C | |
| SCHEMBL3680255 | 0.92 | PDE5A (0.84) | PDE5APDE6C | |
| SCHEMBL6443319 | 0.91 | PDE5A (0.94) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073658-B1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER (US) | 2003-08-13 | — | — | EP | claimed |
| US-6436944-B1 | POTASSIUM CHANNEL OPENERS, AND SILDENAFIL, WHICH ELEVATES CGMP LEVELS | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | claimed |
| US-6271228-B1 | ADMINISTERING PHOSPHODIESTERASE INHIBITOR | PFIZER INC. | 2001-08-07 | — | — | US | claimed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | claimed |
| EP-1090644-A2 | Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cGMP elevator | Pfizer Products Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | claimed |
| US-8513306-B2 | Enhancement of urogenital function | HANDER ROBERT W (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110166232-A1 | ENHANCEMENT OF UROGENITAL FUNCTION | HANDER ROBERT A | 2011-07-07 | — | — | US | disclosed |
| US-20070155837-A1 | Enhancement Of Urogenital Function | HANDER ROBERT W | 2007-07-05 | — | — | US | disclosed |
| US-20060014754-A1 | Methods and compositions for treating diseases and conditions of the eye | PFIZER INC. | 2006-01-19 | — | — | US | disclosed |
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6271228-B1 | ADMINISTERING PHOSPHODIESTERASE INHIBITOR | PFIZER INC. | 2001-08-07 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| EP-1090644-A2 | Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cGMP elevator | Pfizer Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1074258-A2 | Methods and compositions for treating diseases and conditions of the eye | Pfizer Products Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 21/4885 |
| US-20060014754-A1 | Methods and compositions for treating diseases and conditions of the eye | PDE6C, PDE6D, PDE6A | PDE5A 5/4885PDE6C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.